Results 81 to 90 of about 164 (107)

Diroximel fumarate in patients with relapsing–remitting multiple sclerosis: Final safety and efficacy results from the phase 3 EVOLVE-MS-1 study

Multiple Sclerosis Journal, 2023
BACKGROUND: Diroximel fumarate (DRF) is approved for adults with relapsing-remitting multiple sclerosis (RRMS) in Europe and for relapsing forms of MS in the United States.
Douglas L Arnold, Jelena Drulovic, Elżbieta Jasińska   +2 more
exaly   +3 more sources

Diroximel fumarate (DRF) in patients with relapsing–remitting multiple sclerosis: Interim safety and efficacy results from the phase 3 EVOLVE-MS-1 study

Multiple Sclerosis Journal, 2020
BACKGROUND: Diroximel fumarate (DRF) is a novel oral fumarate for patients with relapsing-remitting multiple sclerosis (RRMS). DRF and the approved drug dimethyl fumarate yield bioequivalent exposure to the active metabolite monomethyl fumarate; thus ...
Robert T Naismith, Jerry S Wolinsky, Annette Wundes   +2 more
exaly   +3 more sources

Efficacy and Safety Outcomes with Diroximel Fumarate After Switching from Prior Therapies or Continuing on DRF: Results from the Phase 3 EVOLVE-MS-1 Study

Advances in Therapy, 2022
INTRODUCTION: Diroximel fumarate (DRF) is an oral fumarate for relapsing multiple sclerosis (MS) with the same active metabolite as dimethyl fumarate (DMF).
Florian Then Bergh, Annette Wundes, Douglas L Arnold   +2 more
exaly   +5 more sources

Health-Related Quality of Life with Diroximel Fumarate in Patients with Relapsing Forms of Multiple Sclerosis: Findings from Qualitative Research Using Patient Interviews

Advances in Therapy, 2022
The above graphic abstract represents the opinions of the authors. For a full list of declarations, including funding and author disclosure statements, please see the full text online (see “read the peer-reviewed publication” opposite).
Mark Gudesblatt, Barry A Singer, Sai L Shankar   +2 more
exaly   +2 more sources

Some of the next articles are maybe not open access.

Related searches:

Matching-Adjusted Indirect Comparisons of Diroximel Fumarate, Ponesimod, and Teriflunomide for Relapsing Multiple Sclerosis

CNS Drugs, 2023
Diroximel fumarate (DRF), ponesimod (PON), and teriflunomide (TERI) are oral disease-modifying therapies approved for the treatment of relapsing multiple sclerosis. No randomized trials have compared DRF versus PON or TERI.The objectives of this analysis were to compare DRF versus PON and DRF versus TERI for clinical and radiological outcomes.We used ...
Tammy Jiang, Tjalf Ziemssen, Sibyl Wray, Changyu Shen, Karin Söderbärg, James B. Lewin, Ivan Božin, Mark S. Freedman   +7 more
openaire   +2 more sources

Effect of diroximel fumarate on gut dysbiosis and autoimmunity in the central nervous system

International Immunopharmacology
Diroximel fumarate (DRF) is an approved treatment for relapsing-remitting multiple sclerosis (RRMS). It has demonstrated better gastrointestinal tolerability compared to dimethyl fumarate (DMF). Recent studies indicate that gut dysbiosis may contribute to the development of multiple sclerosis (MS) and that reducing gut dysbiosis may be beneficial for ...
Naoko Itô, Shradha Suresh, Sai L Shankar   +2 more
exaly   +3 more sources

Adverse events analysis of Diroximel fumarate based on FAERS database

Journal of the Neurological Sciences
Haohao Zhu
exaly   +3 more sources

Diroximel Fumarate in Relapsing Forms of Multiple Sclerosis: A Profile of Its Use

CNS Drugs, 2021
Diroximel fumarate (Vumerity®), an orally administered disease-modifying drug (DMD), expands the available treatment options for adults with relapsing forms of multiple sclerosis (MS), including clinically isolated syndrome, relapsing-remitting MS (RRMS), and active secondary progressive MS.
openaire   +2 more sources

Diroximel fumarate – a new twist for MS agent best seller

Progress in Neurology and Psychiatry, 2022
Fast track appraisal (FTA) was adopted by NICE in 2017. This faster and more simplified process is mainly used for novel pharmaceutical agents that are considered bioequivalent to an already recommended drug with added advantages or reduced costs. In June 2022 NICE used FTA to recommend diroximel fumarate (Vumerity) for the management of relapsing ...
openaire   +1 more source

Worsening of lymphopenia in patients with multiple sclerosis when switched from dimethyl fumarate to diroximel fumarate

Multiple Sclerosis and Related Disorders
Diroximel fumarate (DRF) and dimethyl fumarate (DMF) are similar disease-modifying therapies (DMTs) that reduce disease activity in patients with relapsing-remitting multiple sclerosis (MS). We expect that patients on DRF would experience a similar incidence and severity of lymphopenia, given that it is a well-documented side effect of DMF treatment.We
John Dempsey, Alexandra Balshi, Ursela Baber   +2 more
exaly   +3 more sources